Zkusit zdarma
Immatics N.V.

Immatics N.V.

IMTX
Cena:
$ 11.62
+0.56 (5.06%)
Valuace
70
Růst
20
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates

Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates

9:25 12-05-2026

Immatics (IMTX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate...

Immatics Announces First Quarter 2026 Financial Results and Business Update

Immatics Announces First Quarter 2026 Financial Results and Business Update

7:00 12-05-2026

SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggere...

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy

All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy

13:01 06-05-2026

Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the co...

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

10:26 21-04-2026

Houston, Texas and Tuebingen, Germany, April 21, 2026 - Immatics N. V. (NASDAQ: IMTX, "Immatics" or ...

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

10:26 21-04-2026

Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics...

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

15:00 17-04-2026

Individual experimental treatment attempt at Hopp Children's Cancer Center Heidelberg (KiTZ) and Hei...

SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX

SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX

4:45 05-04-2026

SG Americas Securities LLC acquired a new stake in shares of Immatics N.V. (NASDAQ: IMTX) in the fou...

Immatics N.V. (NASDAQ:IMTX) Receives $19.00 Average PT from Analysts

Immatics N.V. (NASDAQ:IMTX) Receives $19.00 Average PT from Analysts

1:31 27-03-2026

Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have earned a consensus recommendation of "...

Immatics (NASDAQ:IMTX) Trading Down 5% – Here’s What Happened

Immatics (NASDAQ:IMTX) Trading Down 5% – Here’s What Happened

4:36 22-02-2026

Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s share price traded down 5% on Friday. The stock tra...

Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of “Moderate Buy” from Analysts

Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of “Moderate Buy” from Analysts

4:09 02-02-2026

Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have been given an average recommendation o...

Immatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy?

Immatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy?

3:38 02-01-2026

Immatics N.V. (NASDAQ: IMTX - Get Free Report) shot up 3.9% on Wednesday. The stock traded as high a...

Immatics: PRAME Leader's Transition To Commercial Reality

Immatics: PRAME Leader's Transition To Commercial Reality

0:04 25-12-2025

Immatics executes a three-wave strategy, progressing from melanoma treatment to broader solid tumors...

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

7:00 11-12-2025

Houston , Texas and Tuebingen, Germany, December 11, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immati...

Immatics Announces $125 Million Underwritten Offering

Immatics Announces $125 Million Underwritten Offering

6:00 05-12-2025

Houston, Texas and Tuebingen, Germany,  December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immat...

Immatics (NASDAQ:IMTX) Sets New 12-Month High – Here’s What Happened

Immatics (NASDAQ:IMTX) Sets New 12-Month High – Here’s What Happened

4:14 05-12-2025

Immatics N.V. (NASDAQ: IMTX - Get Free Report)'s share price hit a new 52-week high on Friday. The s...

Immatics N.V. (NASDAQ:IMTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Immatics N.V. (NASDAQ:IMTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

3:58 19-11-2025

Shares of Immatics N.V. (NASDAQ: IMTX - Get Free Report) have been assigned an average recommendatio...

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

Immatics (IMTX) Reports Q3 Loss, Misses Revenue Estimates

9:16 17-11-2025

Immatics (IMTX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimat...

Immatics Announces Third Quarter 2025 Financial Results and Business Update

Immatics Announces Third Quarter 2025 Financial Results and Business Update

7:00 17-11-2025

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase ...

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

7:00 12-11-2025

Company to host conference call and webcast today, November 12, at 8:30 am EST/2:30 pm CET...

Immatics Appoints Amie Krause as Chief People Officer

Immatics Appoints Amie Krause as Chief People Officer

7:00 27-10-2025

Houston , Texas and Tuebingen, Germany, October 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatic...

close

IMMATICS PRESENTS IMA203CD8 PRAME CELL THERAPY DATA FROM ONGOING DOSE ESCALATION AND SHOWS PROMISING INITIAL ANTI-TUMOR ACTIVITY IN PRAME-POSITIVE TUMORS AT ESMO-IO 2025 CONGRESS

11-12-2025
HOUSTON , TEXAS AND TUEBINGEN, GERMANY, DECEMBER 11, 2025 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATI...
Více zde

IMMATICS ANNOUNCES $125 MILLION UNDERWRITTEN OFFERING

05-12-2025
HOUSTON, TEXAS AND TUEBINGEN, GERMANY,  DECEMBER 05, 2025 – IMMATICS N.V. (NASDAQ: IMTX, “IMMAT...
Více zde

IMMATICS ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE

17-11-2025
ANZU-CEL (ANZUTRESGENE AUTOLEUCEL, IMA203) PRAME CELL THERAPY: GLOBAL, RANDOMIZED, CONTROLLED PHASE ...
Více zde

IMMATICS ACHIEVES CLINICAL PROOF-OF-CONCEPT OF ITS NEXT-GENERATION TCR BISPECIFIC (TCER®) PIPELINE WITH DATA ON IMA402 (PRAME) AND IMA401 (MAGEA4/8) AND ANNOUNCES NEXT DEVELOPMENT STEPS

12-11-2025
COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, NOVEMBER 12, AT 8:30 AM EST/2:30 PM CET...
Více zde

IMMATICS APPOINTS AMIE KRAUSE AS CHIEF PEOPLE OFFICER

27-10-2025
HOUSTON , TEXAS AND TUEBINGEN, GERMANY, OCTOBER 27, 2025 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATIC...
Více zde

IMMATICS HIGHLIGHTS COMPELLING ANTI-TUMOR ACTIVITY OF ANZU-CEL PRAME CELL THERAPY IN METASTATIC UVEAL MELANOMA AT THE ESMO 2025 PRESIDENTIAL SYMPOSIUM

20-10-2025
HOUSTON , TEXAS AND TUEBINGEN, GERMANY, OCTOBER 20, 2025 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATIC...
Více zde

IMMATICS ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE

13-08-2025
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, AUGUST 13, 2025 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATICS...
Více zde

IMMATICS IMA203 PRAME CELL THERAPY DATA PRESENTED AT 2025 ASCO ANNUAL MEETING CONTINUES TO SHOW STRONG ANTI-TUMOR ACTIVITY AND DURABILITY IN PATIENTS WITH METASTATIC MELANOMA

31-05-2025
STAFFORD , TEXAS AND TUEBINGEN, GERMANY, MAY 31, 2025 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATICS...
Více zde

IMMATICS ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATE

13-05-2025
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, MAY 13, 2025 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATICS” ...
Více zde

IMMATICS ANNOUNCES UPCOMING ORAL AND POSTER PRESENTATION ON IMA203 TCR T-CELL THERAPY AT 2025 ASCO ANNUAL MEETING

23-04-2025
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, APRIL 23, 2025 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATICS...
Více zde

IMMATICS ANNOUNCES FULL YEAR 2024 FINANCIAL RESULTS AND BUSINESS UPDATE

27-03-2025
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, MARCH 27, 2025 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATICS...
Více zde

IMMATICS ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS, BUSINESS UPDATE AND FIRST CLINICAL DATA ON TCER® IMA402 TARGETING PRAME

18-11-2024
THE COMPANY WILL NOW TARGET FIVE MAJOR CANCER TYPES WITH ITS FOUR CLINICALLY ACTIVE COMPOUNDS ACROSS...
Více zde

IMMATICS ANNOUNCES MULTIPLE PRESENTATIONS AT THE 39TH ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ON TCR-T THERAPY CANDIDATES TARGETING PRAME

08-11-2024
TWO ORAL PRESENTATIONS AND MULTIPLE POSTERS ON CLINICAL AND PRECLINICAL-STAGE CANDIDATES TO BE PRESE...
Více zde

IMMATICS ANNOUNCES PRICING OF $150 MILLION PUBLIC OFFERING

10-10-2024
H OUSTON, TEXAS AND TUEBINGEN, GERMANY, OCTOBER 10, 2024 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATIC...
Více zde

IMMATICS ANNOUNCES PROPOSED $150 MILLION PUBLIC OFFERING

10-10-2024
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, OCTOBER 10, 2024 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATICS...
Více zde

IMMATICS ANNOUNCES UPDATED PHASE 1B CLINICAL DATA ON ACTENGINE® IMA203 TCR-T TARGETING PRAME IN MELANOMA PATIENTS AND PROVIDES UPDATE ON UPCOMING SUPRAME PHASE 3 TRIAL

10-10-2024
COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, OCTOBER 10, AT 9:00 AM EDT/3:00 PM CEST...
Více zde

IMMATICS ANNOUNCES UPCOMING ORAL AND POSTER PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER ANNUAL MEETING 2024

04-10-2024
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, OCTOBER 4, 2024 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATICS...
Více zde

IMMATICS PRESENTS CLINICAL PROOF-OF-CONCEPT DATA FROM ONGOING PHASE 1 DOSE ESCALATION TRIAL WITH TCR BISPECIFIC MOLECULE TCER® IMA401 TARGETING MAGEA4/8 AT ESMO 2024 AND PROVIDES DEVELOPMENT UPDATE

16-09-2024
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, SEPTEMBER 16, 2024 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATI...
Více zde

IMMATICS ANNOUNCES UPCOMING ORAL PRESENTATION AT THE SOCIETY FOR MELANOMA RESEARCH CONGRESS 2024

06-09-2024
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, SEPTEMBER 06, 2024 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATI...
Více zde

IMMATICS ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND BUSINESS UPDATE

13-08-2024
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, AUGUST 13, 2024 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATICS...
Více zde

IMMATICS ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND BUSINESS UPDATE

14-05-2024
COMPANY PROVIDES CLINICAL DATA UPDATE FROM ONGOING PHASE 1 CLINICAL TRIAL WITH ACTENGINE® IMA203 TC...
Více zde

IMMATICS ANNOUNCES FULL YEAR 2023 FINANCIAL RESULTS AND CORPORATE UPDATE

21-03-2024
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, MARCH 21, 2024 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATICS...
Více zde

IMMATICS ANNOUNCES PRICING OF $175 MILLION PUBLIC OFFERING

17-01-2024
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, JANUARY 17, 2024 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATICS...
Více zde

IMMATICS ANNOUNCES PROPOSED PUBLIC OFFERING

17-01-2024
HOUSTON, TEXAS AND TUEBINGEN, GERMANY, JANUARY 17, 2024 – IMMATICS N.V. (NASDAQ: IMTX, “IMMATIC...
Více zde

IMMATICS ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND BUSINESS UPDATE

14-11-2023
TUEBINGEN, GERMANY AND HOUSTON, TX, NOVEMBER 14, 2023 – IMMATICS N.V. (NASDAQ: IMTX; “IMMATICS...
Více zde

IMMATICS REPORTS INTERIM CLINICAL DATA FROM ACTENGINE® IMA203 AND IMA203CD8 TCR-T MONOTHERAPIES TARGETING PRAME IN AN ONGOING PHASE 1 TRIAL

08-11-2023
COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, NOVEMBER 8, AT 8:30 AM EST/2:30 PM CET...
Více zde

IMMATICS RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION FOR ACTENGINE® IMA203 TCR-T MONOTHERAPY

24-10-2023
RMAT DESIGNATION GRANTED BY FDA CBER FOR IMA203 CELL THERAPY IN MULTIPLE PRAME-EXPRESSING TUMORS INC...
Více zde

PROTALIX BIOTHERAPEUTICS APPOINTS ELIOT RICHARD FORSTER, PH.D. AS CHAIRMAN OF ITS BOARD OF DIRECTORS

12-09-2023
APPOINTMENT EFFECTIVE AS OF SEPTEMBER  14, 2023; ZEEV BRONFELD TO RETIRE FROM THE BOARD OF DIRECTOR...
Více zde

MODERNA AND IMMATICS ANNOUNCE STRATEGIC MULTI-PLATFORM COLLABORATION TO DEVELOP INNOVATIVE ONCOLOGY THERAPEUTICS

11-09-2023
CAMBRIDGE, MASSACHUSETTS AND TUEBINGEN , GERMANY , SEPTEMBER 11 , 2023 – MODERNA, INC. (NASDAQ: MR...
Více zde

IMMATICS ANNOUNCES SECOND QUARTER 2023 FINANCIAL RESULTS AND BUSINESS UPDATE

17-08-2023
TUEBINGEN, GERMANY AND HOUSTON , TX, AUGUST 17 , 2023 – IMMATICS N.V. (NASDAQ: IMTX; “IMMATICS...
Více zde

close

Dokumenty nejsou k dispozici

preloader